

Ohio Department of Job and Family Services (ODJFS)
Drug Utilization Review (DUR) Board
Quarterly Meeting
February 21, 2007

The quarterly meeting of the ODJFS DUR Board was called to order at 12:17 PM in the Tower Conference Room, 30 E. Broad St., Columbus, Ohio. Donald Sullivan, PhD, RPh, Chair, presided. The following Board members were present:

Robert Kubasak, RPh
Kevin Mitchell, RPh
Jacob Palomaki, MD
John Petracci, RPh
Donald Sullivan, PhD, RPh

Also present were Margaret Scott, RPh, DUR Administrator, and Jill Griffith, RPh, DUR Committee Chair. Excused absences were Thomas Gretter, MD, and Lenard Presutti, DO. Twelve observers were present, representing pharmaceutical manufacturers, a college of pharmacy, and ACS State Healthcare.

Reading, Correction & Approval of Previous Minutes:

The November 15, 2006, DUR Board minutes were approved with no corrections. (1st J. Palomaki 2nd J. Petracci).

DUR Committee Report:

The chair of the DUR Committee, Jill Griffith, RPh, gave the DUR Committee report .

J. Griffith reported that during the December 2006 DUR Committee meeting, the Committee reviewed 162 profiles of patients taking three or more oral diabetes drugs concurrently. The committee reviewed profiles for five criteria: doses exceeding those approved by the FDA, use of the first generation sulfonylureas, duplicative therapy, consideration for combination therapy and consideration for insulin therapy. Approximately 69 letters were mailed the week of January 22nd, 2007. The response letters are being collected and evaluated.

J. Griffith reported that during the January 2007 DUR Committee meeting, the Committee reviewed the profiles of 316 diabetic patients on duplicative therapy. Two or more sulfonylureas, a sulfonylurea and a glinide; or a glinide, sulfonylurea and a prandial dosed rapid acting insulin. Approximately 130 letters were mailed the week of February 19th, 2007.

J. Griffith reported that the February 2007 DUR Committee meeting was cancelled due to weather. The Committee will review the profiles of 353 diabetic patients on either Symlin® or Byetta® to assure the drugs are being used according to the FDA approved labeling. This review will take place at the March 13th meeting.

J. Griffith reported the *Ohio DUR Review* was written about the treatment of type 2 diabetes. This educational piece was mailed to all prescribers who received a letter from the DUR Committee regarding the December and January reviews. It will also accompany DUR letters mailed to physicians after the March review of Byetta® and Symlin®. Additionally, ACS educational outreach pharmacists will be calling on those prescribers who received multiple letters from the DUR Committee to discuss the committee's diabetes disease state review.

J. Griffith discussed a tentative review schedule for 2007:

In April, there will be an *Ohio DUR Review* written about the serotonin syndrome to increase prescriber awareness. J. Palomaki requested to review the content of the letter before it is mailed. Dr. Gretter will also be reviewing the content as will the Ohio Medicaid Medical Director. All Board members will receive copies to review before mailing.

In May the DUR Committee will review profiles for duplication of serotonergic triptan therapy. After Board discussion of this point, a profile review for duplicate SSRIs was felt to be more appropriate.

In June, the DUR Committee will review the profiles of patients on Atypical Antipsychotics to determine if metabolic testing (fasting blood glucose and lipid tests) has been taking place over the past year.

During the month of July, the annual report will be put together.

The August DUR review will be focused on appropriate use of telithromycin (Ketek®). The review would target the highest prescribers of telithromycin to educate about the symptoms of liver toxicity and recommend first-line therapy with azithromycin or clarithromycin.

The September review will focus on appropriate use of oseltamivir (Tamiflu®). Letters will be sent to the highest prescribers of oseltamivir prior to the start of flu season.

The October, November and December reviews will address Doctor Shopping which is described as a singular patient receiving controlled substances from multiple physicians.

Health Plan Policy:

M. Scott reported that the Comprehensive NeuroScience (CNS) contract expiring in March will not be renewed. A program evaluation is ongoing at this time. The State is moving to a new electronic system which would render the services CNS provided unnecessary. The Board expressed concern and disappointment with this decision to end the contract before the program evaluation was complete.

ODJFS offices will be moving in April. Therefore, future Board meetings may be held in a different location. The May 23rd meeting is scheduled in the current location. The Board expressed their desire for more parking options.

Unfinished Business:

M. Scott apologized for the delay in Board reimbursement. D. Sullivan confirmed all Board members have received compensation.

New Board members Kevin Mitchell R.Ph. and John Petracci R.Ph. were introduced. There remains one physician vacancy on the Board. M. Scott will continue to work with medical organizations to fill the vacancy.

M. Scott announced that she is researching the requested increase in Board compensation. K. Mitchell added that the Ohio State Board of Pharmacy members are reimbursed at \$180 per day and \$0.40 per mile. M. Scott does not feel that reimbursement of both a stipend and mileage will be possible. M. Scott will work with management to request an increase to approximately \$150 per member per meeting, which is a 50 percent increase. The increase would not be effective before the next fiscal year.

New Business:

J. Griffith requested the Board determine to whom the Serotonin Syndrome *Ohio DUR Review* letter should be mailed. After discussion, it was decided to exempt psychiatrists from the mailing, and to focus on primary care physicians prescribing selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs).

At this time there was also discussion regarding the State's DUR website. The website should be updated to reflect the Board's new membership and to include the diabetes DUR Bulletin.

J. Griffith also asked the Board to think about Chronic Obstructive Pulmonary Disease (COPD); the DUR Committee would like to evaluate drug use for this disease state in 2008.

The Conflict of Interest form was signed by all Board members present.

Announcements:

D. Sullivan announced the next Board meeting would take place on Wednesday, May 23rd at 12:00 noon.

With no further business, the meeting was adjourned at 12:58 PM.

Respectfully submitted:

Jill R.K. Griffith, BS, PharmD, DUR Director